Sectors
PLX
Protalix BioTherapeutics, Inc.
2.57
7500 x 2.59
900 x 2.60
bid
ask
+
0.03
1.18%
4200 @ 07:30 PM
2.60 +0.03 (1.16%)
| Ytd | 42.78% | |
| 1y | 65.81% |
2.52
day range
2.60
1.52
52 week range
3.19
| Open | 2.55 | Prev Close | 2.54 | Low | 2.52 | High | 2.60 | Mkt Cap | 207.07M |
| Vol | 748.35K | Avg Vol | 677.94K | EPS | 0.23 | P/E | 11.17 | Forward P/E | 2.79 |
| Beta | 0.67 | Short Ratio | 22.71 | Inst. Own | 5.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 2.36 | 200-d Avg | 2.23 | 1yr Est | 14.00 |
| Income Statement | |||
| Total Revenue | 19.90M | ||
| Revenues (USD) | 19.90M | ||
| Cost of Revenue | 7.76M | ||
| Gross Profit | 12.13M | ||
| Operating Expenses | 7.46M | ||
| Research and Development Expense | 4.35M | ||
| Selling, General and Administrative Expense | 3.11M | ||
| Operating Income | 4.67M | ||
| Interest Expense | 494.00K | ||
| Income Tax Expense | 1.08M | ||
| Net Income | 3.78M | ||
| Net Income Common Stock | 3.78M | ||
| Net Income Common Stock (USD) | 3.78M | ||
| Consolidated Income | 3.78M | ||
| Earnings per Basic Share | 0.05 | ||
| Earnings per Basic Share (USD) | 0.05 | ||
| Earnings per Diluted Share | 0.05 | ||
| Earning Before Interest & Taxes (EBIT) | 5.35M | ||
| Earning Before Interest & Taxes (USD) | 5.35M | ||
| Weighted Average Shares | 79.99M | ||
| Weighted Average Shares Diluted | 82.56M | ||
| Balance Sheet | |||
| Cash and Equivalents | 28.14M | ||
| Cash and Equivalents (USD) | 28.14M | ||
| Investments | 13.24M | ||
| Investments Current | 13.24M | ||
| Trade and Non-Trade Receivables | 16.50M | ||
| Current Assets | 92.22M | ||
| Property, Plant & Equipment Net | 13.64M | ||
| Total Assets | 110.34M | ||
| Debt Current | 1.67M | ||
| Total Debt | 9.21M | ||
| Current Liabilities | 31.39M | ||
| Debt Non-Current | 7.54M | ||
| Total Liabilities | 38.93M | ||
| Shareholders Equity | 71.40M | ||
| Shareholders Equity (USD) | 71.40M | ||
| Assets Non-Current | 18.12M | ||
| Total Debt (USD) | 9.21M | ||
| Inventory | 32.29M | ||
| Liabilities Non-Current | 7.54M | ||
| Trade and Non-Trade Payables | 29.73M | ||
| Tax Assets | 4.47M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 406.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -13.58M | ||
| Capital Expenditure | -593.00K | ||
| Net Cash Flow from Investing | -3.63M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -3.00M | ||
| Net Cash Flow from Operations | -10.40M | ||
| Effect of Exchange Rate Changes on Cash | 454.00K | ||
| Share Based Compensation | 398.00K | ||